The Emerging Genomic Landscape of Endometrial Cancer
BACKGROUND Endometrial cancer is responsible for ~74,000 deaths amongst women worldwide each year. It is a heterogeneous disease that consists of multiple different histological subtypes. In the United States, the majority of deaths from endometrial carcinoma are attributed to the serous and endometrioid subtypes. An understanding of the fundamental genomic alterations that drive serous and endometrioid endometrial carcinomas lays the foundation for the identification of molecular markers that could improve the clinical management of patients presenting with these tumors. CONTENT Herein we review the current state of knowledge of the somatic genomic alterations that are present in serous and endometrioid endometrial tumors. We present this knowledge in a historical context \xe2\x80\x93 reviewing the genomic alterations that have been identified over the past two decades or more, from studies of individual genes and proteins, followed by a review of very recent studies that have conducted comprehensive, systematic surveys of genomic, exomic, transcriptomic, epigenomic, and proteomic alterations in serous and endometrioid endometrial carcinomas. SUMMARY The recent mapping of the genomic landscape of serous and endometrioid endometrial carcinomas has resulted in the first comprehensive molecular classification of these tumors and has distinguished four molecular subgroups: a POLE ultramutated subgroup, a hypermutated/microsatellite unstable subgroup, a copy number low/microsatellite stable subgroup, and a copy number high subgroup. This molecular classification may ultimately serve to refine the diagnosis and treatment of women with endometrioid and serous endometrial tumors.
Introduction<!>Endometrioid endometrial carcinoma<!>Serous endometrial carcinoma<!>High-grade endometrial carcinoma<!>Molecular Classification of Endometrioid and Serous Endometrial Carcinomas<!>POLE Ultramutated subgroup<!>Hypermutated, microsatellite unstable subgroup<!>Copy number-low, microsatellite stable (MSS) subgroup<!>Copy number-high subgroup<!>Conclusions and future perspectives<!>
<p>Cancers that arise in the body (corpus) of the uterus represent the 8th leading cause of cancer-related death amongst American women, accounting for an estimated 8,190 deaths in 2013 (1). Worldwide, uterine corpus cancers caused approximately 74,000 deaths in 2008 (2). The majority of uterine corpus cancers are endometrial carcinomas, with the remaining cases (3%–5%) being sarcomas (stromal sarcomas, leiomyosarcomas, undifferentiated sarcomas, adenosarcomas) (3). Endometrial carcinomas can be further classified by histology as endometrioid adenocarcinoma, serous adenocarcinoma, clear cell adenocarcinoma, mixed cell carcinoma, mucinous adenocarcinoma, metaplastic carcinoma (carcinosarcoma), squamous cell carcinoma, transitional cell carcinoma, small cell carcinoma, undifferentiated carcinoma, and others (4). The classification of endometrial carcinomas by histological subtype, clinical stage, and grade, is important in assessing prognosis and in deciding the most appropriate treatment regimen (reviewed in (5)).</p><p>In the United States, there is a significant racial disparity in survival from uterine corpus cancer with 5-year relative survival rates of only 57%–63% for African American women compared to 84%–88% for white women (1). This difference in survival is explained at least in part by differences in socioeconomic status, access to health care, and by the fact that, compared with white women, African American women are more likely to be diagnosed with aggressive histological subtypes, including serous carcinomas, clear cell carcinomas, and sarcomas (reviewed in (6)).</p><p>The majority of endometrial carcinomas arise sporadically as a result of acquired somatic alterations. A large, population-based, case-control, genome wide association study has recently identified a locus (rs1202524) on 1q42.2, in the vicinity of the CAPN9 gene, that may be associated with increased risk of endometrial cancer (7).</p><p>A small fraction of endometrial cancers are associated with autosomal dominant, inherited genetic susceptibility in the context of Lynch Syndrome (Hereditary Non-Polyposis Colorectal Cancer; HNPCC) and Cowden Syndrome (8–10). Lynch syndrome is attributed to germline mutations in mismatch repair genes (MLH1, MSH2, MSH6, PMS2), as well as germline deletions of EPCAM that result in transcriptional read-through leading to hypermethylation of the MSH2 promoter, which is located adjacent to EPCAM on chromosome 2p21. In contrast, Cowden Syndrome is linked to germline mutations in the PTEN tumor suppressor gene. In a single institution study, the relative frequency at which endometrioid and non-endometrioid carcinomas occurred in endometrial cancer patients with Lynch Syndrome was similar to their relative frequency in the general population (11). Recently, whole genome sequencing of constitutional DNA from individuals diagnosed with multiple colorectal adenomas by age 60, revealed that a germline mutation (POLD1Ser478Asn) in POLD1, which encodes the catalytic subunit of polymerase δ that promotes lagging strand synthesis during DNA replication, is linked to inherited predisposition to both colorectal cancer and endometrial cancer (12). Several studies have suggested that serous endometrial carcinoma may be a component tumor of Hereditary Breast Ovarian Cancer syndrome (reviewed in (13)). However, there is strong epidemiological evidence that the increased incidence of serous endometrial carcinoma in BRCA1/BRCA2 mutation carriers is associated with prior tamoxifen treatment rather than an underlying genetic susceptibility (14). In this regard, it will be important to also ascertain whether tamoxifen use accounts for any of the documented increased risk to endometrial cancer associated with Cowden syndrome, which also includes breast cancer as a clinical manifestation.</p><p>A detailed discussion of the germline genomic alterations that confer susceptibility to endometrial cancer is the subject of another article in this Special Issue. Here, we will review both the traditional histological classification of endometrioid and serous endometrial carcinomas and the molecular classification of these tumors, which has emerged from a new appreciation of their somatic genomic landscapes (15–20).</p><!><p>Endometrioid endometrial carcinomas represent ~87–90% of all diagnosed endometrial carcinomas (21). They are frequently estrogen-dependent tumors associated with epidemiological risk factors that lead to unopposed estrogen exposure, including obesity, nulliparity, early age at menarche, and late age at menopause (22, 23). They may be preceded by hyperplasia, atypical hyperplasia, and endometrial intraepithelial neoplasia, which is a premalignant outgrowth from benign endometrial hyperplasia (reviewed in (24)). Most endometrioid tumors are diagnosed at an early clinical stage and are associated with an overall favorable prognosis (25). Treatment strategies for endometrioid endometrial carcinoma are guided not only by stage, but also by tumor grade and depth of myometrial invasion since high tumor grade (grade 3) and/or infiltration of more than 50% of the myometrium are predictors of increased risk of tumor recurrence (reviewed in (5)). Treatment for patients with advanced stage or recurrent disease is highly variable (26). The prognosis for advanced stage disease is relatively poor with 5-year overall survival rates of 36%–56% for stage III disease and 21%–22% for stage IV disease noted in one study (25). Although a number of molecularly targeted therapeutics are in clinical trials for endometrial carcinoma (reviewed in (5, 21)), there are currently no FDA-approved targeted therapies for this tumor type.</p><p>Over the past two or more decades, in the era preceding next generation sequencing, much has been done to understand the genetic etiology of endometrioid endometrial carcinomas (reviewed in (24)). Most endometrioid endometrial carcinomas tend to be chromosomally stable with diploid or near-diploid genomes (27). At the molecular level, they are characterized by high frequency genetic alterations in PIK3CA, PIK3R1, and PTEN, resulting in inappropriate activation of the PI3K pathway (28–32). ARID1A, which encodes the BAF250A tumor suppressor, is somatically mutated in 40% of low-grade endometrioid endometrial carcinomas (reviewed in (24)). Loss of BAF250A expression is likewise frequent and has been detected in 19%–34% of endometrioid endometrial carcinomas overall, 26%–29% of low-grade endometrioid endometrial carcinomas, 39% of high-grade endometrioid endometrial carcinomas, and in 16% of endometrial hyperplasias with atypia suggesting that this is an initiating event in endometrioid endometrial tumorigenesis ((33–35) and reviewed in (24)). Other signal transduction pathways that are frequently disrupted in endometrioid endometrial carcinomas include the RAS-RAF-MEK-ERK pathway, resulting from somatic mutations in KRAS (~18% of cases) or hypermethylation of the RASSF1A promoter (62–74% of cases) ((36) and reviewed in (24)). Somatic mutations in the FGFR2 receptor tyrosine kinase occur in ~12% of endometrioid endometrial carcinomas and are mutually exclusive with KRAS mutations (36, 37). Although mutual exclusivity implies functional redundancy, the clinical correlates of KRAS and FGFR2 mutations are different, indicating possible differences in their biological effects (36). The canonical WNT signaling pathway is often disrupted in endometrioid endometrial carcinomas, resulting from somatic mutation of CTNNB1 (2%–45% of cases) and stabilization of β-catenin (36, 38, 39). It has recently been shown that CTNNB1 and KRAS mutations are mutually exclusive in endometrioid ECs, leading to the proposal that there may be functional cross-talk between the RAS-RAF-MEK-ERK and WNT/TCF signaling pathways in this cell type, or functional redundancy in the biological consequences of altered RAS-RAF-MEK-ERK and WNT/TCF signaling (36). Endometrioid tumors also often exhibit microsatellite instability (MSI) with an incidence of 34% MSI-positivity noted in a recent large single-institution study of 466 cases (36), and 40% MSI-positivity noted among endometrioid endometrial carcinomas selected for analysis by The Cancer Genome Atlas (15). The MSI phenotype in sporadic endometrial carcinomas is attributed to defective mismatch repair primarily resulting from hypermethylation of the MLH1 promoter, as well as low frequency somatic mutations in MSH6 and loss of MSH2 expression (40–42).</p><!><p>Serous endometrial carcinomas are high-grade tumors that are often metastatic at presentation and have an associated 5-year relative survival rate of only 44.7%, compared to 91.2% for endometrioid endometrial carcinoma (43). Although they are rare at diagnosis, serous carcinomas are clinically aggressive and contribute substantially to mortality from endometrial cancer. In one study, serous tumors constituted only 10% of endometrial cancer diagnoses but accounted for 39% of deaths (44). Recent epidemiological evidence suggests that, similar to endometrioid endometrial carcinoma, increased body mass index may be a risk factor for serous endometrial carcinoma (23). Serous endometrial carcinomas may be preceded by precancerous cells with a so-called "p53 signature", by endometrial glandular dysplasia, or by endometrial intraepithelial carcinoma (reviewed in (45)). Treatment approaches for serous endometrial carcinoma are variable but generally include surgical staging and cytoreduction followed by adjuvant chemotherapy and/or radiotherapy (reviewed in (46, 47)).</p><p>Although the genomic landscape of serous endometrial carcinoma has recently been deciphered (15–18), prior molecular studies of individual genes and pathways established that serous endometrial carcinomas are characterized by a high frequency (up to 90% of cases) of somatic mutations in TP53 and/or p53 stabilization (48, 49). TP53/p53 abnormalities are believed to be initiating events in the development of serous endometrial cancer based on their occurrence in premalignant cells, in endometrial glandular dysplasia, and in endometrial intraepithelial carcinoma (reviewed in (24)). Consistent with the idea that p53 dysregulation is an initiating event in serous endometrial tumorigenesis, mice with conditional deletion of Trp53 in the genitourinary tract develop non-endometrioid endometrial carcinomas including serous carcinomas (50). In addition to p53 alterations, human serous endometrial carcinomas also harbor frequent somatic mutations in PPP2R1A, which encodes a subunit of the PP2A phosphatase, and in PIK3CA, PIK3R1 and PTEN within the PI3-kinase pathway (reviewed in (24)). Overexpression of the cell cycle proteins cyclin E and p16, amplification and overexpression of the ERBB2 receptor tyrosine kinase, loss of expression of BAF250A, and altered expression of the cell adhesion proteins claudin-3, claudin-4, L1CAM, EpCAM, and E-cadherin have also been documented (reviewed in (24)).</p><!><p>A substantial proportion of high-grade endometrial carcinomas can be difficult to reproducibly classify according to histological subtype (reviewed in (51)). For example, one study noted discordant subtype classification in approximately one-third of high-grade endometrial tumors (52). The difficulty in unambiguously classifying some high-grade endometrial carcinomas is problematic because different histological subtypes have different clinical behaviors and different treatment considerations (reviewed in (53)). Immunochemical phenotyping for markers such as p53, ER, PR, PTEN, IMP3, and p16 may serve as informative adjuncts to traditional histopathology for the classification of high-grade endometrial tumors since unambiguously assigned histological subtypes tend to show characteristic differences in the expression patterns of these markers (54–56). In the future, mutational profiles may also be useful adjuncts to histopathological classification. For example, significant differences have been noted in the frequency of mutations among ARID1A, PTEN, PIK3CA, PPP2R1A, TP53, and CTNNB1 in low-grade endometrioid endometrial carcinoma, high-grade endometrioid endometrial carcinoma, serous endometrial carcinoma, and endometrial carcinosarcomas, and the pattern of mutations in this six-gene set facilitated the histological reclassification of some endometrial tumors (57). In a combined analysis of immunohistochemical staining of grade 3 endometrioid endometrial carcinomas for MLH1, MSH2, p16, cyclin D1, ERBB2, WT1 and p53, 37% of cases had molecular profiles that resembled endometrioid carcinomas whereas 63% of cases resembled serous carcinomas at the molecular level (58). As we will discuss later in this review, the integrated genomic analysis of endometrioid and serous endometrial carcinomas by The Cancer Genome Atlas (TCGA) revealed that 19.6% of histologically classified high-grade (grade 3) endometrioid endometrial carcinomas in that study have genomic profiles that resemble those of serous carcinomas (15).</p><!><p>Although much has been done to understand the molecular etiology of endometrial carcinomas over the past several decades, the very recent application of next generation sequencing to comprehensively search for somatic alterations in endometrial carcinomas has resulted in a rapid, and significant shift in our understanding of the molecular events underlying these tumors. Beginning in 2012, a number of studies, including one from our own group, reported the results of systematic searches for somatic mutations among the ~22,000 protein-encoding genes that constitute the exome, in serous and endometrioid endometrial carcinomas (16–20). The first large-scale, fully integrated genomic analysis of endometrial carcinomas was reported in 2013 by TCGA (15) and employed whole exome resequencing, whole transcriptome sequencing, genome-wide copy number analysis, expression profiling, reverse phase protein array (RPPA), methylation profiling, and an assessment of microsatellite instability to interrogate 186 endometrioid, 42 serous, and 4 mixed histology endometrial carcinomas in an integrated manner (15). A subset of TCGA tumors (n=107) was also subjected to low-pass whole genome sequencing to identify structural variants. Together, these studies provided critical new insights into the molecular features of serous and endometrioid endometrial carcinomas including the first observation, reported by TCGA, that endometrial carcinomas can be broadly classified into four distinct molecular subgroups based on an integrated analysis of somatic mutation rates, frequency of copy number alterations, and microsatellite instability status. In the following sections we provide an overview of the most salient features of the four molecular subgroups identified by TCGA, which are defined as "POLE ultramutated", "hypermutated/microsatellite unstable", "copy number low/microsatellite stable", and "copy number high (serous-like)".</p><!><p>As their name suggests, ultramutated tumors have an extraordinarily high mutation rate (232 × 10−6 mutations per Mb; 867 to 9,714 mutations per tumor), and an elevated incidence of C>A transversions (15). Overall, 6.4% of low-grade endometrioid endometrial carcinomas and 17.4% of high-grade endometrioid endometrial carcinomas, but none of the mixed histology or serous tumors in the TCGA study, were ultramutated. The ultramutated phenotype is attributed to somatic mutations in the exonuclease domain of POLE which encodes the catalytic and proof-reading subunit of the polymerase epsilon holoenzyme that catalyzes leading strand synthesis during DNA replication and regulates cell cycle progression, chromatin remodeling, and DNA repair (59). In an earlier study, Church et al., described somatic mutations in the exonuclease domain of POLE in 7% of endometrioid, 25% of serous, and 33% of mixed histology endometrial carcinomas, although it should be noted that the total number of serous and mixed histology tumors in that study was small (60). Church et al., further noted a significant increase in the incidence of POLE mutations with high tumor grade (4.7% grade 1 tumors versus 1.7% grade 2 tumors versus 22.2% grade 3 tumors; P=0.001) (60).</p><p>TCGA uncovered 190 significantly mutated genes (defined in that study as having a convolution test false discovery rate of 2% or less) among the POLE/ultramutated tumors. Significantly enriched pathways (p-value < 1×10−2) associated with this subgroup involve gluconeogenesis, glycolysis, clathrin-mediated endocytosis signaling, tRNA charging, the TCA cycle II (eukaryotic), and actin cytoskeleton signaling. Although the number of ultramutated endometrial carcinomas that have been described thus far is small, it is noteworthy that the progression-free survival of patients in the ultramutated subgroup is more favorable than for other molecular subgroups (hypermutated/MSI, copy number low/MSS, or copy number high/serous-like) (15).</p><!><p>The so-called hypermutated/MSI endometrial cancer subgroup is composed of microsatellite unstable tumors that have low-level somatic copy number alterations (15). Consistent with their microsatellite instability phenotype, the hypermutated/MSI subgroup also displays frequent MLH1 promoter methylation and reduced MLH1 gene expression. Hypermutated/MSI tumors are also associated with a heavily methylated subgroup, suggestive of a CpG methylator phenotype (CIMP). In the TCGA tumor cohort, 28.6% of low-grade endometrioid endometrial carcinomas and 54.3% of high-grade endometrioid endometrial carcinomas were within the hypermutated/MSI subgroup. This observation is consistent with earlier reports that MSI-positivity occurs at significantly higher frequency in high-grade endometrioid ECs compared with low-grade endometrioid ECs (61–63). None of the mixed histology or serous endometrial carcinomas in the TCGA cohort were within the hypermutated/MSI subgroup (15). The absence of serous ECs from the hypermutated/MSI subgroup is in accordance with the infrequent (0%–4%) occurrence of MSI documented in serous tumors by TCGA and in earlier analyses of other large cohorts of serous EC (15, 18, 57, 64).</p><p>Twenty-one significantly mutated genes (candidate pathogenic driver genes) have been identified in the hypermutated/MSI subgroup (Table 1), including 11 genes (ARID5B, CSDE1, CTCF, GIGYF2, HIST1H2BD, LIMCH1, MIR1277, NKAP, RBMX, TNFAIP6, ZFHX3) that were not previously known to be significantly mutated in endometrial carcinoma. Most of the remaining significantly mutated genes (PTEN, PIK3CA, PIK3R1, ARID1A, RPL22, KRAS, CTNNB1, ATR, FGFR2, CCND1) have well-documented roles in the endometrioid subtype as discussed earlier in this review and elsewhere (24, 65). RPL22 has an emergent role in endometrioid endometrial carcinomas. Somatic mutations at a polynucleotide tract within RPL22, resulting in protein truncation, were previously demonstrated to occur in 52% of MSI-high endometrioid endometrial carcinomas, and to correlate with later age at diagnosis (67 versus 63 years, p=0.0005) (66). Although the functional effect of RPL22 mutations in endometrial cancer remains to be determined, it is noteworthy that RPL22 has been suggested to be a haploinsufficient tumor suppressor gene based on observations that 10% of primary T-ALLs exhibit monoallelic deletion of RPL22 and that haploinsufficiency for RPL22 accelerates tumorigenesis in a mouse model of T cell lymphoma (67).</p><p>In addition to significantly mutated genes, a number of significantly enriched pathways are recognized in the hypermutated/MSI subgroup including the threonine degradation II, glycine degradation, and anandamide degradation pathways. The RTK (Receptor Tyrosine Kinase)/RAS/β-catenin pathway is altered in 69.5% of hypermutated/MSI tumors and the PIK3CA-PIK3R1-PTEN axis is genomically altered in 95.5% of cases. As noted previously, targeted therapies directed against the PI3-kinase pathway are currently being evaluated in clinical trials for the treatment of endometrial cancer (reviewed in (21)). KRAS alterations, which may confer resistance to PI3K-pathway inhibitors (reviewed in (68)), is mutated or amplified in 35% of hypermutated/MSI endometrial tumors (15). An earlier large study of endometrioid endometrial carcinomas demonstrated that somatic mutations in KRAS and FGFR2 were statistically significantly more frequent among MSI-positive than MSI-negative endometrioid tumors whereas mutations in CTNNB1 were significantly more frequent among MSI-negative tumors (36).</p><p>Historically, there has been considerable interstudy variability regarding whether or not MSI status is associated with clinical outcome of endometrial cancer. Factors proposed to account for this variability include differences in the numbers of patients between studies was well as differences in the histopathological composition of study cohorts (61). However, a recent large single-institution study, exclusively composed of endometrioid endometrial cancers, observed no significant correlation between MSI status and either overall survival or disease-free survival (61). Moreover, a recently published meta-analysis of 23 studies, including the latter study (61), observed no significant correlation between MSI and clinical outcome for endometrial cancer (69).</p><!><p>The copy number-low/microsatellite stable subgroup described by TCGA included 60.0% of low-grade endometrioid carcinomas, 8.7% of high-grade endometrioid carcinomas, 2.3% of serous carcinomas, and 25% of mixed histology carcinomas. Sixteen significantly mutated genes were discerned in this molecular subgroup (Table 1), consisting of nine genes previously implicated in endometrial cancer (PTEN, PIK3CA, CTNNB1, ARID1A, PIK3R1, KRAS, FGFR2, CHD4, SPOP) by ourselves and others ((17, 18) and reviewed in (24)), and seven genes (BCOR, CSMD3, CTCF, MECOM, METTL14, SGK1, SOX17) that had not previously been recognized to have a role in endometrial tumorigenesis. However, even though significantly mutated genes are generally indicative of probable pathogenic driver genes, it is should be cautioned that the designation of CSMD3 as a significantly mutated gene in endometrial cancer likely reflects the inadequacy of statistical algorithms to account for the observations that late-replicating genes and lowly-expressed genes, such as CSMD3, exhibit higher background mutation rates than early replicating genes or highly expressed genes (70). As such, the designation of CSMD3 as a significantly mutated gene in endometrial cancer likely reflects an elevated background mutation rate rather than the accumulation of pathogenic driver mutations (70).</p><p>Almost all (92%) tumors in this subgroup have somatically altered the PI3K pathway. KRAS is altered in 16% of cases, which is considerably lower than the frequency of KRAS mutation in the MSI+/hypermutated ECs, in keeping with earlier observations that KRAS mutations are significantly more common in microsatellite-unstable versus microsatellite-stable EECs (36). The RTK/RAS/β-catenin pathway is also altered at high frequency (83%) among MSS/copy number low tumors and, within this pathway, somatic mutations in CTNNB1 are particularly prevalent (52%). Mutations in SOX17, which regulates β-catenin levels, are observed exclusively in this subgroup.</p><!><p>In the TCGA study, 5.0% of low-grade endometrioid carcinomas, 19.6% of high-grade endometrioid carcinomas, 97.7% of serous carcinomas, and 75% of mixed histology carcinomas were in the copy number-high tumor subgroup. That almost all serous ECs in the TCGA study are deemed copy number-high is consistent with previous reports that serous ECs are often aneuploid and chromosomally unstable (16, 17, 71, 72).</p><p>Eight significantly mutated genes have been described among the 60 copy number high/serous-like tumors in the TCGA study, including CSMD3, which, as discussed earlier in this review, probably reflects a statistical artifact rather than a bona fide driver gene (Table 1). The other significantly mutated genes in the serous-like subgroup were TP53, PIK3CA, PTEN, PIK3R1, and PPP2R1A, which have well-established roles in serous EC (reviewed in (24)), and FBXW7 and CHD4 which we and others previously identified as significantly mutated genes in serous endometrial carcinomas (16–18). With the exception of CHD4, each of the aforementioned genes is a bona fide cancer gene. As has previously been noted for TP53, the presence of somatic mutations within FBXW7, PIK3CA, and PPP2R1A in serous intraepithelial carcinoma and concurrent serous endometrial carcinomas implicates mutation of these genes as early events in the development of serous endometrial cancer (16). The functional consequences of mutations in CHD4, which encodes the catalytic subunit of the NuRD chromatin-remodeling complex, remain to be elucidated. However, the designation of CHD4 as a significantly mutated gene in serous and serous-like tumors (15, 17, 18), and the presence of mutation hotspots within this gene, strongly suggest that it is likely to be a causal driver gene.</p><p>Other genes that have emerged as significantly mutated genes in whole exome sequencing studies of serous endometrial carcinomas are SPOP, a putative tumor suppressor gene, CDKN1A, a bona fide cancer gene, TAF1, HCFC1R1, CTDSPL, YIPF3, and FAM132A (17,18). In terms of biological processes, our group has shown that genes that are involved in chromatin-remodeling and ubiquitin-mediated protein degradation are frequently mutated in serous endometrial tumors (18). That is not to say that chromatin-remodeling genes and ubiquitin ligase complex genes are not also perturbed in the endometrioid subtype; indeed, a number of chromatin-remodeling genes, such as ARID1A, ARID5B, CTCF, and CHD4, are also causal or candidate driver genes in molecular subgroups dominated by endometrioid endometrial tumors (Table 1).</p><p>Using statistical methods, a number of genomic regions of significant copy number alteration have been defined in serous-like tumors including regions of focal amplification involving the MYC oncogene, the ERBB2 (HER2) receptor tyrosine kinase gene, and CCNE1 (Cyclin E1), which are each focally amplified in 23%–25% of cases (15). The mutual exclusivity in serous EC of CCNE1 amplification and somatic alterations affecting FBXW7, which normally mediates the ubiquitin-mediated degradation of Cyclin E, suggests that these genetic events are functionally redundant (16). The observation of frequent MYC, ERBB2, and CCNE1 gene amplification in serous-like endometrial carcinomas is consistent with prior observations in serous endometrial carcinomas (16, 17, 24). Numerous additional genes of interest, including PIK3CA, FBXW7, CHD4, and MBD3, are located within larger regions of copy number alteration in serous and serous-like endometrial carcinomas (15–17).</p><p>Copy number-high endometrial tumors have a DNA methylation pattern similar to that of the normal endometrium. A large proportion (85%) of tumors in the copy number high subgroup are also within a so-called mitotic subgroup defined by altered mRNA expression of genes involved in cell cycle regulation (15). RNA sequencing has also revealed transcriptional differences that form significantly enriched pathways in the copy number high subgroup including G1/S checkpoint regulation, growth hormone signaling, Her-2 signaling in breast cancer, endothelin-1 signaling, cyclins and cell cycle regulation, and molecular mechanisms of cancer (15). Furthermore, in the serous-like molecular subgroup, increased levels of p53, and decreased levels of phospho-AKT have been noted by RPPA analysis (15).</p><p>The simultaneous assessment of the entire complement of protein-encoding genes by TCGA revealed that most of the ERBB2-amplified serous-like tumors also were PIK3CA-mutant (P=0.038). As noted (15), the co-occurrence of ERBB2 amplification and PIK3CA mutation in serous-like tumors may be clinically relevant because in ERBB2-overexpressing breast cancer cell lines, activating mutations in PIK3CA are associated with decreased sensitivity to trastuzumab and to lapatinib, therapeutic agents that target ERBB2 (73, 74). This illustrates the importance of evaluating the larger genomic context of druggable targets when, for example, considering the design and interpretation of clinical trials assessing targeted therapies. A small number of studies have assessed the clinical efficacy of trastuzumab for the treatment of ERBB2-positive advanced or recurrent endometrial cancer (reviewed in (75)) and additional clinical trials of trastuzumab or lapatinib in endometrial cancer are ongoing or planned (NCT01367002; NCT01454479). As these and other trials of targeted therapies directed against ERBB2 in endometrial cancer proceed, it may be useful to assess whether PIK3CA mutation status impacts clinical response. The PIK3CA-PIK3R1-PTEN axis itself is altered in 73% of copy number high/serous-like tumors whereas KRAS is mutated or amplified in 8% of serous-like tumors (15). The clinical efficacy of therapeutic agents targeting the PI3K/AKT/mTOR pathway in the treatment of endometrial cancer has recently been reviewed elsewhere (68).</p><p>One of the most interesting findings from the genomic analysis of endometrial tumors is that approximately one-fifth of tumors that were classified as grade 3 endometrioid endometrial carcinomas are "serous-like" at the molecular level. As noted in the TCGA study, the distinction between the histological and molecular classification of these cases has important clinical implications - suggesting that patients with grade 3 endometrioid endometrial carcinomas that have a serous-like genomic profile might be more appropriately treated with regimens that are used for serous carcinoma. As discussed earlier in this review, a subset of high-grade endometrial tumors are difficult to classify accurately by subtype at the histological level. The newfound realization that serous and endometrioid endometrial tumors can be molecularly classified into four distinct subgroupings may provide future opportunities to devise a panel of biomarkers, or indeed use integrated genomic profiling, to augment traditional histopathologic classification of endometrial carcinomas. In this regard, it is notable that 48 significantly mutated genes are altered at differential frequency across the four molecular subgroups of endometrial carcinoma reported by TCGA (Table 2). How the genomic profiles of endometrioid and serous endometrial carcinomas relate to the genomic profiles of other endometrial carcinoma subtypes remains to be determined.</p><!><p>In the past year, the pace of mutation discovery in endometrial cancer has been unprecedented. To date, the exomes of 96 serous and 233 endometrioid endometrial carcinomas have been deciphered (15–20). The integrated genomic analysis of these two subtypes of endometrial cancer by The Cancer Genome Atlas (15), as well as studies from individual laboratories (16–20), has provided unprecedented insights into the genomic, epigenomic, transcriptomic, and proteomic alterations that are present in serous and endometrioid endometrial tumors. Together these studies have given the endometrial cancer community the most comprehensive view of the genomic landscape of this disease thus far. It is likely that our view of this landscape, and the genetic and biological context of the alterations that shape it, will continue to be refined and defined by the functional annotation of candidate cancer genes that have emerged from these studies and by the sequencing of additional endometrial tumors, including rare histological subtypes. Prospective studies assessing the potential clinical utility of these findings will undoubtedly follow. One could envision that the molecular classification of endometrial tumors might assist in guiding a determination of prognosis and treatment decisions, in the discovery of new druggable targets and pathways, and in implementing molecular diagnostics to detect endometrial cancers an earlier stage in their clinical course when prognosis is more favorable. In the latter case it is noteworthy that the genomic analysis of cells collected during Papanicolaou (PAP) tests holds promise for the early detection of endometrial carcinomas (19). In future studies it will also be important to decipher the genomic landscape of metastatic disease, and of precancerous lesions that precede endometrial carcinomas, as well as annotating and functionalizing somatic aberrations in the non-coding regions of the genome in endometrial carcinomas.</p><!><p>Significantly mutated genes (SMGs) in three molecular subgroups of endometrial cancer (15)</p><p>Probable false-positive (70)</p><p>48 SMGs mutated at differential frequency across four molecular subgroups of serous and endometrioid endometrial cancers (15)</p><p>Mutation frequency of protein-encoding genes was retrieved using cBioPortal (URL: http://www.cbioportal.org/public-portal/); mutation frequency of MIR1277 was retrieved using the TCGA data portal (URL: https://tcga-data.nci.nih.gov/tcga/).</p><p>Probable false-positive (70)</p>